Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
22 August 2017 - 10:00PM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that
the Company will participate in five upcoming investor conferences.
Paratek is a biopharmaceutical company focused on the development
and commercialization of innovative therapies based upon
tetracycline chemistry. Paratek’s Chief Commercial Officer, Adam
Woodrow, will present at:
- Baird’s 2017 Global Healthcare Conference on
Thursday, September 7 from 2:00 p.m. to 2:30 p.m. at the
InterContinental New York Barclay. To access the live webcast of
Paratek’s Baird presentation, please visit
http://wsw.com/webcast/baird49/prtk.
Paratek’s President, Chief Operating Officer and Chief Medical
Officer, Evan Loh, MD, will present at the following events:
- Rodman & Renshaw Annual Global Investment
Conference on Monday, September 11 from 10:25 a.m. to
10:50 a.m. at the Lotte New York Palace. To access the live webcast
of Paratek’s Rodman & Renshaw presentation, please visit
http://wsw.com/webcast/rrshq27/prtk.
- Morgan Stanley Annual Global Healthcare
Conference on Tuesday, September 12 from 5:15 p.m. to 5:45
p.m. at the Grand Hyatt New York. To access the live webcast of
Paratek’s Morgan Stanley presentation, please
visit https://cc.talkpoint.com/morg007/091117a_as/?entity=62_7OCNEK2.
- Cantor Fitzgerald Annual Healthcare Conference
on Monday, September 25 from 10:55 a.m. to 11:25 a.m. at the
InterContinental New York Barclay. To access the live webcast of
Paratek’s Cantor Fitzgerald presentation, please visit
http://wsw.com/webcast/cantor6/prtk.
- Ladenburg Thalmann Healthcare Conference on
Tuesday, September 26 from 9:00 a.m. to 9:25 a.m. at the Sofitel
Hotel New York. To access the live webcast of Paratek’s Ladenburg
Thalmann presentation, please visit
http://wsw.com/webcast/ladenburg3/prtk.
Replays of each webcast can be accessed up to 90 days following
the live presentations.
About ParatekParatek Pharmaceuticals,
Inc. is a biopharmaceutical company focused on the development
and commercialization of innovative therapies based upon its
expertise in novel tetracycline chemistry. The Company’s lead
product candidate, omadacycline, is a new, once-daily oral and
intravenous broad-spectrum antibiotic being developed for the
treatment of serious community-acquired bacterial infections,
including community-acquired bacterial pneumonia (CABP), acute
bacterial skin and skin structure infections (ABSSSI), and urinary
tract infections. Omadacycline has been granted Qualified
Infectious Disease Product designation and Fast Track status by
the U.S. Food and Drug Administration for the target
indications. Paratek has completed Phase 3 development activities
for omadacycline in CABP and ABSSSI and is preparing to submit
marketing applications in the United States and European Union.
Paratek has licensed rights for omadacycline to Zai Lab for the
greater China region, and retains all remaining global rights.Under
a research agreement with the U.S. Department of Defense,
omadacycline also is being studied against pathogenic agents
causing infectious diseases of public health and biodefense
importance, including plague and anthrax.Paratek's second Phase 3
product candidate, sarecycline, is being developed by Allergan in
the U.S. as a new once-daily oral therapy for the treatment of
acne. Allergan has completed Phase 3 development activities
for sarecycline and is preparing a new drug application for
submission to the U.S. Food and Drug Administration. Paratek
retains all ex-U.S. rights to sarecycline.Recognizing the serious
threat of bacterial infections, Paratek is dedicated to providing
solutions that enable positive outcomes and lead to better patient
stories. For more information, visit www.paratekpharma.com or
follow @ParatekPharma on Twitter.
CONTACTS:
Media Relations:
Michael Lampe
(484) 575-5040
michael@scientpr.com
Investor Relations:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2024 to May 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From May 2023 to May 2024